Rhizome AIWinter 2026Active☆Watch⊞Compare

Rhizome AI is one of 2067 AI / ML companies tracked from New York City, NY, USA; Remote, on record since 2026. By capital raised it ranks mid-pack (ahead of 62% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%

operates a technology-led product inferred from public copy

Grounded in: “You are a venture analyst”

Agent Platform for Life Sciences

It takes 500,000 days of office work to bring a drug to market. We want to make it 5. To get there, we need agents doing most of the work. Today, our research agent is the best way to know what the FDA thinks. Users ask a question and get an answer backed by up to 1,000 documents, where each statement has a citation. It’s the best because we have the best retrieval engine. We’ve tuned it on our life science-specific dataset, and we find what others miss. As more teams use Rhizome, we gain more data on what regulatory professionals actually need, which makes retrieval even better. This flywheel is how we become the retrieval engine that powers all human and agent work in life sciences. Chetan started his career as a research engineer, but quickly realized he enjoyed building more than research. He joined EvolutionaryScale as their sole founding product engineer, launching their developer-scientist platform and scaling to tens of thousands of users and billions of API calls. He was also #16 at Instabase helping banks with document processing, closing $7m as the technical closer. Agents can do magical things today, but most in life sciences only use them to edit emails. Agents are missing the context they need to 100x the number of drugs we can bring to market. Rhizome AI is focused on that critical problem.

As reported in public records reported — not modeled.

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

No round amounts on record to chart.

No staged rounds to sequence.

Round size and date are reported; the stage label is inferred from round size. Valuation is modeled from stage benchmarks. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Benchmarked against 2067 companies in AI / ML. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Raised more than 62% of sector peers (real $). Modeled value above 62% of peers (estimate).

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Rhizome AI is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

See where Rhizome AI sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

If you work at Rhizome AI, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.